Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance 15 January 2022 from 5 AM to 1 PM EST. Store functionality may be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 13 November 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has announced another proposed study of consumers who watch drug advertising on TV—the second this week—this time trying to assess how spouses influence how consumers understand a drug's benefits and risks.
FDA frequently studies consumer behavior as it related to drug advertising. An overview of recent studies is as follows:
FDA's various studies have focused in large part on the ways in which consumers view DTC advertising, and how a wide range of factors can impact their assessment of a drug's benefits and risks.
Unlike most of the studies FDA has proposed since 2012, FDA's latest proposal focuses on the "social contexts" in which a direct-to-consumer advertisement is seen. Specifically, FDA notes that a "potential consumer and his or her spouse (e.g. marital or domestic partner) may view an ad together and discuss drug benefits, side effects and risks."
"These social interactions may result in unique reactions relative to consumers who view DTC prescription drug ads alone," FDA continues in its 13 November 2014 Federal Register notice. A person's spouse, for example, may express their concern about a particular risk posed by a drug, leading the person to take a more negative view of the drug.
To study whether spouses have an effect on how a drug's benefits and risks are perceived, FDA's Office of Prescription Drug Promotion (OPDP) plans to study participants under a variety of conditions.
Participants will be shown one of two advertisements: one which depicts a low-benefit and low-risk drug, and another depicting a high-benefit and high-risk drug. Patients will be randomly assigned to either view the ad alone or with their spouse, FDA said. Participants viewing the ad with their spouse will be given time to discuss the ad together before answering a survey.
The study will focus on patients with asthma. Spousal participants in the study should not have the condition, FDA said.
Federal Register notice
Tags: DTC Advertising, OPDP, Study, Drug Advertising, Spouse
Regulatory Focus newsletters
All the biggest regulatory news and happenings.